Cuttable and consumable tape-type or bar-type preparation enabling drug dose control through length

Abstract

The present invention relates to a cuttable and consumable tape-type or bar-type preparation containing a pharmacologically active ingredient, and, more specifically, to: a tape-type or bar-type preparation enabling precise drug dose control through tape or bar length; and a method for controlling drug dose through length by using the preparation. The tape-type or bar-type preparation of the present invention has cut lines formed at equal intervals in the longitudinal direction, and contains uniform drug doses according to predetermined lengths, thereby enabling accurate dose measurement customized to the age and the weight of an administration subject (children or adults) and enabling easy cutting by the hands and consumption. That is, in the tape-type or bar-type preparation of the present invention, the length of the tape or bar and the drug dose are proportional to each other so that the length required in administering an appropriate dose according to the age and the weight of an administration subject (children or adults) can be easily measured and cut, and thus errors in dose calculation can be minimized and side effects can be reduced. In addition, the tape-type or bar-type preparation of the present invention is a semi-solid formulation and, unlike a liquid formulation, is easy to hold and be consumed without spillage, has excellent storage stability, and is easy to store and carry.

Description

Cuttable tape or bar-shaped preparations that allow for adjustable drug dosage through length

[0001] The present invention relates to a tape-type or bar-type preparation that can be cut and eaten, including a pharmacologically active ingredient, and more particularly, to a tape-type or bar-type preparation that allows for precise drug dosage control through the length of the tape or bar; and a method for controlling the dosage of a drug through the length using the preparation.

[0002] Common medications for children kept at home include runny nose drops, cough syrups, fever reducers, cold remedies, and antihistamines. Unlike adults, children require smaller doses of medication and often have difficulty swallowing pills. Furthermore, dosages need to be adjusted accordingly, as weight and height vary with age. For this reason, pharmaceutical companies offer syrup formulations, which are easier to measure by volume, rather than tablets, which are more difficult to adjust. Currently, the dosage volumes for commonly sold syrup formulations vary from 2.5 to 20.0 mL, depending on weight and age. This significant variation in dosage across children's weight and age makes it difficult for pharmaceutical companies to develop customized formulations for specific age groups.

[0003] Recently, problems such as layer separation and clumping have emerged in cough syrup formulations. This is due to the instability of liquid formulations. Furthermore, syrup-type medications are difficult to store, and their liquid form means a shorter shelf life than solid formulations. Furthermore, they are prone to spillage, which can make administration difficult for parents. While cough syrup is currently the most suitable formulation for children, it still faces several challenges.

[0004] Syrup packaging on the market can be divided into multiple-dose and single-dose containers. Multiple-dose containers contain a large volume of medication in a single bottle. This type of packaging is cumbersome, requiring the syrup to be dispensed and measured each time the medication is administered. Because they contain a large volume and are usually heavy, they are also less portable. Furthermore, repeated opening and closing of the cap can lead to contamination. Some products utilize measuring cups as caps to facilitate dosing, but this presents a challenge: cleaning the cup after administration. Single-dose containers, on the other hand, contain a single dose in a single container. While disposable and convenient, they reduce the risk of contamination, and offer additional challenges. Because the appropriate dosage varies depending on a child's age and weight, failure to properly manage this can lead to overdose or underdose. This can lead to adverse side effects and inadequate treatment.

[0005] Therefore, the risks associated with administering cough syrup arise from various aspects, including dosage adjustment issues, drug composition issues, and packaging issues, and a new approach is needed to address all of these issues.

[0006] Against this backdrop, the inventors of the present invention sought to develop a solid dosage form to replace the existing cold medicine syrups that have the various problems described above, and as a result, designed a tape-type or bar-type formulation in which secants are formed at equal intervals along the length direction. In the case of the tape-type or bar-type formulation, since a uniform amount of drug is included according to a certain length, an accurate dosage measurement suitable for the age and weight of the administration subject (child or adult) is possible, and since it can be easily cut and eaten by hand, and since it is a semi-solid formulation, it has excellent storage stability and is easy to store and carry, thereby completing the present invention.

[0007] Accordingly, the purpose of the present invention is to provide a tape-type or bar-type preparation that can be easily cut and eaten by hand and that enables accurate dosage measurement according to the age and weight of the subject of administration (child or adult) by forming dividing lines at equal intervals along the length direction.

[0008] Another object of the present invention is to provide a method for controlling the precise dosage of a drug through length using the tape-type or bar-type preparation.

[0009] In order to achieve the above purpose of the present invention,

[0010] A tape-type preparation containing a pharmacologically effective ingredient and having cut lines formed at equal intervals along the length direction is provided.

[0011] In one embodiment of the present invention, the formulation may have segments formed at equal intervals along the length, thereby enabling the drug dosage to be controlled through the length.

[0012] In one embodiment of the present invention, the pharmacologically effective ingredient may include at least one selected from the group consisting of acetaminophen, acetylsalicylic acid, phenylephrine hydrochloride, dextromethorphan hydrobromide hydrate, chlorpheniramine maleate, pseudoephedrine hydrochloride, dl-methylephedrine hydrochloride, dextromethorphan, guaifenesin, chlorperastine hydrochloride, S-ibuprofen, dextromethorphan hydrobromide, noscapine hydrochloride, trimethoquinone hydrochloride, carbetapentane citrate, tipepidine citrate, phenylephedrine hydrochloride, phenylpropanolamine, dexibuprofen, phenacetin, oxymetazoline, chlorperastine phendizoate, d-chlorpheniramine, triprolidine, carbinoxamine, phenylephrine hydrochloride, and brompheniramine maleate.

[0013] In one embodiment of the present invention, the formulation may further include at least one selected from the group consisting of a film forming agent, a plasticizer, a flavoring agent, a flavor modifier, a sweetener, a colorant, a suspending agent, a pH regulator, a nutrient, a lubricant, a preservative, an antiseptic, an emulsifier, a wetting agent, a surfactant, and a buffering agent.

[0014] In addition, the present invention provides a method for controlling the dosage of a drug through length using the tape-type preparation.

[0015] In addition, the present invention provides a bar-type preparation containing a pharmacologically effective ingredient and having cut lines formed at equal intervals along the length direction.

[0016] In one embodiment of the present invention, the formulation may have segments formed at equal intervals along the length, thereby enabling the drug dosage to be controlled through the length.

[0017] In one embodiment of the present invention, the pharmacologically effective ingredient may include at least one selected from the group consisting of acetaminophen, acetylsalicylic acid, phenylephrine hydrochloride, dextromethorphan hydrobromide hydrate, chlorpheniramine maleate, pseudoephedrine hydrochloride, dl-methylephedrine hydrochloride, dextromethorphan, guaifenesin, chlorperastine hydrochloride, S-ibuprofen, dextromethorphan hydrobromide, noscapine hydrochloride, trimethoquinone hydrochloride, carbetapentane citrate, tipepidine citrate, phenylephedrine hydrochloride, phenylpropanolamine, dexibuprofen, phenacetin, oxymetazoline, chlorperastine phendizoate, d-chlorpheniramine, triprolidine, carbinoxamine, phenylephrine hydrochloride, and brompheniramine maleate.

[0018] In one embodiment of the present invention, the formulation may further include at least one selected from the group consisting of a film forming agent, a plasticizer, a flavoring agent, a flavor modifier, a sweetener, a colorant, a suspending agent, a pH regulator, a nutrient, a lubricant, a preservative, an antiseptic, an emulsifier, a wetting agent, a surfactant, and a buffering agent.

[0019] In addition, the present invention provides a method for controlling the dosage of a drug through length using the bar type formulation.

[0020] The tape-type or bar-type preparation of the present invention has secants formed at equal intervals along the length direction, and contains a uniform amount of drug according to a certain length, so that it has the advantage of being able to accurately measure the dosage according to the age and weight of the subject of administration (children or adults) and being able to be easily cut and eaten by hand. That is, in the case of the tape-type or bar-type preparation of the present invention, since the length of the tape or bar and the amount of drug are proportional, the length required to administer an appropriate dosage according to the age and weight of the subject of administration (children or adults) can be easily measured and cut, thereby having the advantage of minimizing errors in dosage calculation and reducing side effects. In addition, the tape-type or bar-type preparation of the present invention is a semi-solid formulation, so that it is easy to hold and eat without spilling, unlike a liquid formulation, and has the advantage of being excellent in storage stability as well as being easy to store and carry.

[0021] Figure 1 is a schematic diagram showing a tape-type preparation of the present invention.

[0022] Figure 2 is a schematic diagram of a tape-type preparation of the present invention, in which dividing lines are marked at equal intervals along the length of the tape to accurately measure the dosage according to age and weight (dotted lines: 0.5, 1.5, 2.5, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5, 9.5 cm, solid lines: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 cm).

[0023] Figure 3 is a schematic diagram of a bar type formulation with equal intervals marked along the length of the bar to allow for accurate dosage measurement according to age and weight.

[0024] FIG. 4 is a photograph showing a tape-type or bar-type preparation having a jelly formulation manufactured through Example <1-1> of the present invention.

[0025] Figure 5 is a photograph showing a bar type preparation having a gummy formulation manufactured through Example <1-2> of the present invention.

[0026] The present invention relates to a tape-type or bar-type preparation containing a pharmacologically effective ingredient and having cut lines formed at equal intervals along the length direction.

[0027] In one specific embodiment of the present invention, the formulation has segments formed at equal intervals along the length, so that the drug dose can be controlled through the length.

[0028] The tape-type or bar-type preparation of the present invention contains a uniform amount of pharmacologically effective ingredients throughout, and each section formed at equal intervals according to the dosage can be checked and taken according to the exact dosage.

[0029] Each section can be designed to be cut accurately by inserting a secant line of a certain length (e.g., 0.5 cm or 1.0 cm) for easy division, and even if a secant line is not inserted, the dosage form itself is soft (flexible), so it can be safely divided with just a little force. Each section is marked in cm like a ruler, so that the length can be easily recognized. This method allows the user to easily measure the required amount of drug. This has the effect of greatly improving the inaccurate method of measuring the dosage by taking an appropriate amount of liquid syrup.

[0030] The pharmacologically effective ingredient of the present invention may include an antipyretic, analgesic or anti-inflammatory agent as an effective ingredient that can alleviate, improve or treat a cold.

[0031] In one specific example of the present invention, the pharmacologically effective ingredient may be at least one selected from the group consisting of acetaminophen, acetylsalicylic acid, phenylephrine hydrochloride, dextromethorphan hydrobromide hydrate, chlorpheniramine maleate, pseudoephedrine hydrochloride, dl-methylephedrine hydrochloride, dextromethorphan, guaifenesin, chlorperastine hydrochloride, S-ibuprofen, dextromethorphan hydrobromide, noscapine hydrochloride, trimethoquinone hydrochloride, carbetapentane citrate, tipepidine citrate, phenylephedrine hydrochloride, phenylpropanolamine, dexibuprofen, phenacetin, oxymetazoline, chlorperastine phendizoate, d-chlorpheniramine, triprolidine, carbinoxamine, phenylephrine hydrochloride, and brompheniramine maleate.

[0032] In addition to the pharmacologically effective ingredients described above, the formulation of the present invention may further contain film forming agents, plasticizers, flavoring agents, flavor modifiers, sweeteners, coloring agents, suspending agents, pH regulators, nutrients, lubricants, preservatives, antiseptics, emulsifiers, wetting agents, surfactants, salts and / or buffers for osmotic pressure control, and other therapeutically useful substances known in the art.

[0033] In the present invention, the film forming agent may be selected from the group consisting of pullulan, gelatin, pectin, low viscosity pectin, hydroxypropyl methylcellulose, low viscosity hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, polyacrylic acid, methyl methacrylate copolymer, carboxyvinyl polymer, polyethylene glycol, alginic acid, low viscosity alginic acid, sodium alginate, modified starch, casein, whey protein isolate, soy protein isolate, zein, levan, elsinan, gluten, acacia gum, carrageenan, gum arabic, guar gum, locust bean gum, xanthan gum, gellan gum, and agar.

[0034] In the present invention, a plasticizer can be used to control the flexibility of the film, and the plasticizer can be selected from the group consisting of sorbitol, maltitol, xylitol, glycerin, polyethylene glycol, propylene glycol, hydrogenated corn syrup, starch syrup, glycerin, triacetin, glycerol oleate, sucrose fatty acid ester, and medium-chain fatty acids.

[0035] Flavoring agents in the present invention include compounds and complexed mixtures of these compounds that impart a desired flavor to edible products. Examples include freeze-dried natural plant ingredients, essential oils, essences, extracts, natural and synthetic flavorings (including natural flavorings) in the form of powders, and may include acids and other substances that can affect the flavor profile. Examples of liquid and powdered flavorings include coconut, coffee, chocolate, vanilla, grape, orange, lime, peppermint, licorice, caramel, honey, peanut, walnut, cashew, hazelnut, almond, pineapple, strawberry, raspberry, tropical fruit, cherry, cinnamon, peppermint, wintergreen, spearmint, eucalyptus, and mint, and fruit essences such as apple, pear, peach, strawberry, apricot, raspberry, cherry, pineapple, and plum essences. Essential oils include peppermint, spearmint, menthol, eucalyptus, clove, bay, anise, thyme, cedar leaf, nutmeg, and the aforementioned fruit oils.

[0036] In the present invention, the flavor modifier includes a compound known in the field of flavor chemistry that modifies the perception of the taste of other compounds, such as a bitter taste masking agent.

[0037] In the present invention, the sweetener may be a sugar sweetener, a non-sugar sweetener, a high-sweetness artificial sweetener, etc.

[0038] The above sugar sweeteners may include saccharide-containing ingredients commonly known in the chewing gum art, including but not limited to sucrose, dextrose, maltose, dextrin, trehalose, D-tagatose, dried invert sugar, fructose, levulose, galactose, corn syrup solids, or mixtures thereof, used alone or in combination.

[0039] The non-saccharide sweetener may be sorbitol. Other useful non-saccharide sweeteners include, but are not limited to, other sugar alcohols, such as mannitol, xylitol, hydrogenated starch hydrolysates, maltitol, isomaltol, erythritol, lactitol, and the like, either singly or in mixtures.

[0040] The high-potency artificial sweeteners described above may also be used alone or in combination with the above sweeteners. Preferred high-potency sweeteners include, but are not limited to, single compounds or combinations of sucralose, aspartame, acesulfame salts, alitame, saccharin and its salts, neotame, cyclamic acid and its salts, glycyrrhizin, dihydrochalcone, thaumatin, monellin, and sterioside.

[0041] In one specific embodiment of the present invention, sugar can be used to provide sweetness to improve medication compliance. However, alternative sweeteners such as xylitol, aspartame, and saccharin can be used to reduce or eliminate the white sugar content. This can help children maintain healthy teeth and eating habits, and reduce the risk of obesity and other metabolic diseases. Completely replacing white sugar can also allow for the design of a dosage form that can be administered before bed without brushing.

[0042] In addition, the present invention relates to a method for controlling the dosage of a drug through length using a tape-type or bar-type preparation as described above.

[0043] In one specific embodiment of the present invention, a tape-type or bar-type preparation containing acetaminophen as a pharmacologically active ingredient has sections formed at equal intervals along the length, wherein each section can contain 16 mg of acetaminophen at intervals of 1 cm. In this case, the dosage of the drug can be adjusted based on the length as follows.

[0044]

[0045] - 4-6 months: 7-7.9kg, 80mg, 5cm

[0046] - 7-23 months: 8-11.9kg, 120mg, 7.5cm

[0047] - 2-3 years old: 12-15.9kg, 160mg, 10cm

[0048] - Ages 4-6: 16-22.9kg, 240mg, 15cm

[0049] - Ages 7-8: 23-29.9kg, 320mg, 20cm

[0050] - Ages 9-10: 30-37.9kg, 400mg, 25cm

[0051] - 11 years old: 38-42.9kg, 480mg, 30cm

[0052] - Ages 12 and older: 43 kg or more, 640 mg, 40 cm

[0053]

[0054] The above criteria are only examples; the dosage of the drug contained in each equal interval may vary depending on the drug type, composition, and manufacturing method. Measuring the length of a solid (semi-solid) dosage form enables accurate drug administration, ensuring effective treatment while minimizing adverse drug reactions.

[0055]

[0056] Hereinafter, the present invention will be described in more detail through examples. These examples are intended to more specifically illustrate the present invention, and the scope of the present invention is not limited to these examples.

[0057] <Example>

[0058]

[0059] ingredient

[0060] Acetaminophen, glycerol, and sodium carboxymethylcellulose were purchased from Sigma-Aldrich. Ibuprofen was purchased from Tokyo Chemical Industry. Gelatin was purchased from Duksan Pure Chemical. Xylitol, corn starch, DL-malic acid, natural strawberry flavor powder, grape flavor, red pigment RP, and purple grape color were purchased from ES Food Ingredients.

[0061]

[0062] High-performance liquid chromatography (HPLC) analysis conditions

[0063] The concentration of acetaminophen was analyzed using a Waters HPLC system (Milford, MA, USA) equipped with a 2996 photodiode array detector and a 2695 separation module. A Fortis C18 chromatography column (5 μm, 4.6 × 250 mm) was used for the analysis, and the column temperature was maintained at 30°C. A 10 μL HPLC injection volume was used for acetaminophen. The mobile phase consisting of pH 4.7 / MeOH (80:20, v / v) was eluted isocratically at a flow rate of 1.0 mL / min. Acetaminophen was detected at a wavelength of 240 nm.

[0064] The concentration of ibuprofen was analyzed using an Agilent HPLC 1260 series (Agilent Technologies, USA). A Fortis C18 chromatography column (5 μm, 4.6 × 250 mm) was used for the analysis, and the column temperature was maintained at 25°C. A 20 μL HPLC injection volume was used for ibuprofen. The mobile phase consisting of MeOH / DW / Phosphoric acid (75:24.7:0.3, v / v) was eluted isocratically at a flow rate of 1.0 mL / min. Ibuprofen was detected at a wavelength of 264 nm.

[0065]

[0066] <Example 1>

[0067] Tape-type or bar-type preparation of the present invention

[0068]

[0069] <1-1> Jelly production

[0070] Dissolve gelatin in water and soak for about 10 minutes, then double boil at 100℃ until completely dissolved. Then, heat at 100℃ and mix the main ingredient (acetaminophen or ibuprofen), xylitol, DL-malic acid, glycerol, flavoring agent (natural strawberry flavor powder or grape flavor), and food coloring (red pigment RP, purple grape color). Then, add water equivalent to the evaporated amount to produce a tape composition with uniform content overall.

[0071] The above composition was shaped using a mold and hardened in a refrigerator at 4°C for 24 hours.

[0072] Afterwards, xylitol powder prepared by mixing xylitol / corn starch (95:5, w / w) in a mixer was mixed with the above composition.

[0073] Finally, slits were formed at even intervals along the length of the jelly.

[0074] The composition and content of the jelly formulation of the present invention are shown in detail in Tables 1 and 2 below, and Fig. 4 shows a cold medicine in the jelly formulation actually manufactured.

[0075]

[0076] <1-2> Manufacturing of gums

[0077] Xylitol powder was prepared by mixing xylitol / corn starch / sodium carboxymethyl cellulose (95:5:1, w / w) in a mixer.

[0078] Dissolve gelatin in water and soak for about 10 minutes, then heat in a double boiler at 100℃ until completely dissolved. Then, heat at 100℃ and mix the main ingredient (acetaminophen or ibuprofen), DL-malic acid, glycerol, flavoring (natural strawberry flavor powder or grape flavor), and food coloring (red pigment RP, purple grape color). Then, add the amount of water that has evaporated.

[0079] The prepared xylitol powder was mixed with the above composition, and a dough was made using a kneader, then wrapped and stored at room temperature for 24 hours.

[0080] After that, the dough was made into a certain size through a molding machine.

[0081] The components and contents of the gummy formulation of the present invention are shown in detail in Tables 1 and 2 below, and Fig. 5 shows a cold medicine in the gummy formulation actually manufactured.

[0082]

[0083] Composition and content of each dosage form of tape-type or bar-type preparations manufactured using acetaminophen 1cm (unit: mg) G1G2J1J2Acetaminophen 16.00 16.00 16.00 16.00 16.00 Xylitol 110.67 126.67 200.00 240.00 Corn Starch 6.67 6.67 -- Gelatin 4.00 4.00 33.20 33.20 Sodium carboxymethylcellulose 1.33 1.33 -- Distilled water 26.67 26.67 174.00 134.00 DL-malic acid 1.33 1.33 4.00 4.00 Glycerol 20.00 20.00 52.00 52.00 Flavoring 0.13 0.130 400.40 Food coloring 0.13 0.130 400.40 G: Gummy formulation, J: Jelly formulation

[0084]

[0085] Composition and content of each dosage form of tape-type or bar-type preparations manufactured using ibuprofen 1cm (unit: mg) G1G2J1J2Ibuprofen 10.00 10.00 10.00 10.00 10.00 Xylitol 116.67 126.67 198.00 262.00 Corn Starch 6.67 6.67 -- Gelatin 4.00 4.00 33.20 20.00 Sodium carboxymethyl cellulose 1.33 1.33 -- Distilled water 26.67 26.67 178.00 127.20 DL-malic acid 1.33 1.33 4.00 4.00 Glycerol 20.00 20.00 56.00 56.00 Flavoring 0.130 130 400 40 Food coloring 0.130 130 400 40 G: Gummy formulation, J: Jelly formulation

[0086]

[0087] <1-3> Content of drug in the formulation

[0088] The drug content of each formulation was determined by mixing 1 cm of each formulation in 20 ml of a solvent consisting of Ph4.7 / MeOH (80:20, v / v) at 60°C for 30 minutes, and then filtering the solution through a 0.2 μm sieve. The acetaminophen concentration of each formulation was determined using the HPLC described above.

[0089] The drug content of each formulation was determined by mixing 1 cm of each formulation with 20 ml of MeOH at 60°C for 30 minutes, and then filtering the solution with a 0.2 μm sieve. The ibuprofen concentration of each formulation was determined using the HPLC described above.

[0090]

[0091] Drug content (mg) by dosage form (n=10) G1G2J1J2Acetaminophen15.46±0.6916.72±0.4116.01±0.4015.67±0.30Ibuprofen10.11±0.7410.41±0.8510.15±0.529.88±0.77G: Gummy dosage form, J: Jelly dosage form

[0092]

[0093] <Example 2>

[0094] Dosage measurement method using the tape-type or bar-type preparation of the present invention

[0095] A standard for measuring the exact dosage according to the body weight and age of the subject of administration was presented using the formulation prepared through the above <Example 1>.

[0096]

[0097] Drug dosage and length of tape (or bar) of tape-type or bar-type preparations manufactured using acetaminophen Age Body weight Drug dosage Length of tape or bar 4-6 months 7-7.9 kg 80 mg 5 cm 7-2 3 months 8-11.9 kg 120 mg 7.5 cm Only 2-3 years 12-15.9 kg 160 mg 10 cm Only 4-6 years 16-22.9 kg 240 mg 15 cm Only 7-8 years 23-29.9 kg 320 mg 20 cm Only 9-10 years 30-37.9 kg 400 mg 25 cm Only 11 years 38-42.9 kg 480 mg 30 cm

[0098]

[0099] Drug dosage and length of tape (or bar) of tape-type or bar-type preparations manufactured using ibuprofen Age Drug dosage Length of tape or bar 4-23 months 50-100 mg 5-10 cm Only 2-5 years 100-150 mg 10-15 cm Only 6-9 years 150-200 mg 15-20 cm Only 10-13 years 200-250 mg 20-25 cm

[0100]

[0101] As described above, the length of the formulation to be cut can be set corresponding to the child's weight and age.

[0102]

[0103] The present invention has been described above, focusing on preferred embodiments thereof. Those skilled in the art will appreciate that the present invention can be implemented in modified forms without departing from its essential characteristics. Therefore, the disclosed embodiments should be considered illustrative rather than limiting. The scope of the present invention is set forth in the claims, not the foregoing description, and all differences within the scope equivalent thereto should be construed as being encompassed by the present invention.

Claims

1. Contains pharmacologically effective ingredients, A tape-type preparation in which cut lines are formed at equal intervals along the length.

2. In paragraph 1, The above formulation is a tape-type formulation characterized in that the drug dosage can be controlled through the length by forming dividing lines at equal intervals along the length.

3. In paragraph 1, A tape-type preparation characterized in that the above pharmacologically effective ingredient comprises at least one selected from the group consisting of acetaminophen, acetylsalicylic acid, phenylephrine hydrochloride, dextromethorphan hydrobromide hydrate, chlorpheniramine maleate, pseudoephedrine hydrochloride, dl-methylephedrine hydrochloride, dextromethorphan, guaifenesin, chlorperastine hydrochloride, S-ibuprofen, dextromethorphan hydrobromide, noscapine hydrochloride, trimethoquinone hydrochloride, carbetapentane citrate, tipepidine citrate, phenylephedrine hydrochloride, phenylpropanolamine, dexibuprofen, phenacetin, oxymetazoline, chlorperastine phendizoate, d-chlorpheniramine, triprolidine, carbinoxamine, phenylephrine hydrochloride, and brompheniramine maleate.

4. In paragraph 1, A tape-type preparation characterized in that the above preparation further comprises at least one selected from the group consisting of a film-forming agent, a plasticizer, a flavoring agent, a flavor modifier, a sweetener, a colorant, a suspending agent, a pH regulator, a nutrient, a lubricant, a preservative, an antiseptic, an emulsifier, a wetting agent, a surfactant, and a buffering agent.

5. A method for controlling the dosage of a drug through length using a tape-type preparation according to any one of claims 1 to 4.

6. Contains pharmacologically effective ingredients, A bar-type preparation in which slits are formed at equal intervals along the length.

7. In paragraph 6, The above formulation is a bar-type formulation characterized in that the drug dosage can be controlled through the length by forming dividing lines at equal intervals along the length.

8. In paragraph 6, A bar type preparation characterized in that the above pharmacologically effective ingredient comprises at least one selected from the group consisting of acetaminophen, acetylsalicylic acid, phenylephrine hydrochloride, dextromethorphan hydrobromide hydrate, chlorpheniramine maleate, pseudoephedrine hydrochloride, dl-methylephedrine hydrochloride, dextromethorphan, guaifenesin, chlorperastine hydrochloride, S-ibuprofen, dextromethorphan hydrobromide, noscapine hydrochloride, trimethoquinone hydrochloride, carbetapentane citrate, tipepidine citrate, phenylephrine hydrochloride, phenylpropanolamine, dexibuprofen, phenacetin, oxymetazoline, chlorperastine phendizoate, d-chlorpheniramine, triprolidine, carbinoxamine, phenylephrine hydrochloride, and brompheniramine maleate.

9. In paragraph 6, A bar type preparation characterized in that the above preparation further comprises at least one selected from the group consisting of a film forming agent, a plasticizer, a flavoring agent, a flavor modifier, a sweetener, a coloring agent, a suspending agent, a pH regulator, a nutrient, a lubricant, a preservative, an antiseptic, an emulsifier, a wetting agent, a surfactant, and a buffering agent.

10. A method for controlling the dosage of a drug through length using a bar type formulation of any one of claims 6 to 9.

Images